504 results on '"Xie, Junxia"'
Search Results
2. Contrasting Iron Metabolism in Undifferentiated Versus Differentiated MO3.13 Oligodendrocytes via IL-1β-Induced Iron Regulatory Protein 1
3. Intracerebroventricular injection of α-synuclein preformed fibrils do not induce motor and olfactory impairment in C57BL/6 mice
4. Potential convergence of olfactory dysfunction in Parkinson’s disease and COVID-19: The role of neuroinflammation
5. Ndfip1 protected dopaminergic neurons via regulating mitochondrial function and ferroptosis in Parkinson's disease
6. Dopaminergic neurodegeneration in the substantia nigra is associated with olfactory dysfunction in mice models of Parkinson’s disease
7. Linking Genetic Risks to Pathological α-Synuclein Transmission in Parkinson’s Disease
8. 4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson’s Disease
9. Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease
10. Iron Overload Causes Ferroptosis But Not Apoptosis in MO3.13 Oligodendrocytes
11. Updates on brain regions and neuronal circuits of movement disorders in Parkinson’s disease
12. TFEB regulates cellular labile iron and prevents ferroptosis in a TfR1-dependent manner
13. Chemogenetic and optogenetic stimulation of zona incerta GABAergic neurons ameliorates motor impairment in Parkinson’s disease
14. Estrogen Up-Regulates Iron Transporters and Iron Storage Protein Through Hypoxia Inducible Factor 1 Alpha Activation Mediated by Estrogen Receptor β and G Protein Estrogen Receptor in BV2 Microglia Cells
15. Calcium Homeostasis in Parkinson’s Disease: From Pathology to Treatment
16. Expanding Views of Mitochondria in Parkinson’s Disease: Focusing on PINK1 and GBA1 Mutations
17. Yeast Prion Protein Sup35 Initiates α‐Synuclein Pathology in Parkinson's Disease
18. Desferrioxamine Ameliorates Lipopolysaccharide-Induced Lipocalin-2 Upregulation via Autophagy Activation in Primary Astrocytes
19. Ferritin confers protection against iron-mediated neurotoxicity and ferroptosis through iron chelating mechanisms in MPP+-induced MES23.5 dopaminergic cells
20. Targeting the Cuneiform Nucleus in Parkinson’s Disease: Option to Improve Locomotor Activity
21. Extracellular α-Synuclein Modulates Iron Metabolism Related Proteins via Endoplasmic Reticulum Stress in MES23.5 Dopaminergic Cells
22. New Insights into the Role of Ferritin in Iron Homeostasis and Neurodegenerative Diseases
23. Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease
24. Ferritin Is Secreted from Primary Cultured Astrocyte in Response to Iron Treatment via TRPML1-Mediated Exocytosis
25. Alpha-Synuclein Handling by Microglia: Activating, Combating, and Worsening
26. Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation
27. Regulated cell death: discovery, features and implications for neurodegenerative diseases
28. Ghrelin Reduces A-Type Potassium Currents in Dopaminergic Nigral Neurons via the PLC/PKCδ Pathway
29. Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease
30. Axonal Iron Transport might Contribute to Iron Deposition in Parkinson’s Disease
31. Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2
32. Alpha-synuclein Affects Certain Iron Transporters of BV2 Microglia Cell through its ferric reductase activity
33. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model
34. Commentary: The impact of iron deposition on the fear circuit of the brain in patients with Parkinson's disease and anxiety
35. Intraperitoneal injection of iron dextran induces peripheral iron overload and mild neurodegeneration in the nigrostriatal system in C57BL/6 mice
36. The S-nitrosylation of parkin attenuated the ubiquitination of divalent metal transporter 1 in MPP+-treated SH-SY5Y cells
37. Heme oxygenase‐1: The roles of both good and evil in neurodegenerative diseases.
38. Potassium Channels: A Potential Therapeutic Target for Parkinson’s Disease
39. Ndfip1 attenuated 6-OHDA–induced iron accumulation via regulating the degradation of DMT1
40. Iron Overload Causes Ferroptosis But Not Apoptosis in MO3.13 Oligodendrocytes
41. Iron, Dopamine, and α-Synuclein Interactions in at-Risk Dopaminergic Neurons in Parkinson’s Disease
42. Transdermal Adhesive Patches Loaded with Ketoprofen Evaluated by Dynamic Detection of Percutaneous Absorption
43. Brain Iron Metabolism Dysfunction in Parkinson’s Disease
44. Ghrelin and Neurodegenerative Disorders—a Review
45. Preferential Heme Oxygenase-1 Activation in Striatal Astrocytes Antagonizes Dopaminergic Neuron Degeneration in MPTP-Intoxicated Mice
46. Assessments of plasma ghrelin levels in the early stages of parkinsonʼs disease
47. Dopamine in Parkinson’s Disease: Precise Supplementation with Motor Planning
48. Ligand-independent interaction of the type I interferon receptor complex is necessary to observe its biological activity
49. Ceruloplasmin is Involved in the Nigral Iron Accumulation of 6-OHDA-Lesioned Rats
50. High hepcidin level accounts for the nigral iron accumulation in acute peripheral iron intoxication rats
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.